share_log

Ginkgo Bioworks | 10-Q: Q1 2024 Earnings Report

Ginkgo Bioworks | 10-Q: Q1 2024 Earnings Report

Ginkgo Bioworks | 10-Q:2024财年一季报
美股SEC公告 ·  05/09 16:22

Moomoo AI 已提取核心信息

Ginkgo Bioworks Holdings, Inc. reported a decrease in total revenue for the first quarter ended March 31, 2024, with revenues falling to $37.944 million from $80.702 million in the same period last year. The company's Cell Engineering segment saw a decrease in revenue from $34.096 million to $27.889 million, while the Biosecurity segment's revenue dropped significantly from $46.606 million to $10.055 million. The total segment operating loss widened to $123.662 million from $116.410 million year-over-year. The diluted net loss per share remained constant at $0.08, improving from a net loss of $0.11 per share in the previous year. Ginkgo Bioworks also reported a net loss of $165.911 million, an improvement from a net loss of $204.969 million in the first quarter of 2023. The company has undertaken restructuring actions to reduce...Show More
Ginkgo Bioworks Holdings, Inc. reported a decrease in total revenue for the first quarter ended March 31, 2024, with revenues falling to $37.944 million from $80.702 million in the same period last year. The company's Cell Engineering segment saw a decrease in revenue from $34.096 million to $27.889 million, while the Biosecurity segment's revenue dropped significantly from $46.606 million to $10.055 million. The total segment operating loss widened to $123.662 million from $116.410 million year-over-year. The diluted net loss per share remained constant at $0.08, improving from a net loss of $0.11 per share in the previous year. Ginkgo Bioworks also reported a net loss of $165.911 million, an improvement from a net loss of $204.969 million in the first quarter of 2023. The company has undertaken restructuring actions to reduce operational expenditures, including labor expense reductions and facility consolidations, expected to commence in the second quarter of 2024. Additionally, Ginkgo acquired platform assets from AgBiome, Inc. on April 10, 2024, to enhance its Ag Biologicals Services. Looking forward, Ginkgo Bioworks aims to leverage its Foundry and Codebase assets to drive scale and learning efficiencies across diverse markets, with a focus on improving the probability of successful product development for its customers.
Ginkgo Bioworks Holdings, Inc.报告称,截至2024年3月31日的第一季度总营业收入下降,收入从去年同期的8080.2万美元降至3794.4万美元。该公司的电芯工程业务收入从3409.6万美元下降至2788.9万美元,而生物安全业务的收入从4660.6万美元急剧下降至1005.5万美元。总部门运营亏损从去年同期的11641万美元扩大至12366.2万美元。稀释净亏损每股保持不变,为0.08美元,较上年同期每股净亏损0.11美元有所改善。Ginkgo Bioworks的净亏损也从2023年第一季度的20496.9万美元有所改善,下降至16591.1万美元。该公司已经采...展开全部
Ginkgo Bioworks Holdings, Inc.报告称,截至2024年3月31日的第一季度总营业收入下降,收入从去年同期的8080.2万美元降至3794.4万美元。该公司的电芯工程业务收入从3409.6万美元下降至2788.9万美元,而生物安全业务的收入从4660.6万美元急剧下降至1005.5万美元。总部门运营亏损从去年同期的11641万美元扩大至12366.2万美元。稀释净亏损每股保持不变,为0.08美元,较上年同期每股净亏损0.11美元有所改善。Ginkgo Bioworks的净亏损也从2023年第一季度的20496.9万美元有所改善,下降至16591.1万美元。该公司已经采取重组行动以降低运营支出,包括削减劳动力费用和设施整合,预计将于2024年第二季度开始。此外,Ginkgo于2024年4月10日收购了AgBiome,Inc的平台资产,以增强其农业生物服务。未来,Ginkgo Bioworks旨在利用其Foundry和Codebase资产,在不同的市场上推动规模和学习效率,关注提高客户产品开发成功率。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息